NEW YORK (GenomeWeb News) — Orchid Cellmark today said third-quarter revenues decreased 4 percent as R&D spending declined 16 percent and losses fell 65 percent.
Total receipts for the three months ended Sept. 30 decreased to $15.7 million from $16.4 million year over year.
R&D spending decreased to $316,000 from $376,000 year over year.
The company said losses declined to $1.3 million from $3.8 million in the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.